Furthermore, the pattern of IL-17+, IFNγ+ and IL-4+ CD4+T-lymphocytes production detected in new-onset DMARD-naïve RA patients could be modified by MTX treatment, and two different behaviors were identified in responders and nonresponders. This evidence concerns the gene IFNG and rheumatoid arthritis.